Novelion therapeutics inc. (NVLN)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Net revenues

130,432

138,438

-

-

-

-

-

-

-

-

Cost of product sales

59,697

77,220

-

-

-

-

-

-

-

-

Net revenues

-

-

13,574

0

0

-

-

-

-

42,106

Revenues

-

-

-

-

-

-

-

-

-

42,106

Cost of product sales

-

-

5,971

0

0

-

-

-

-

20,198

Operating expenses:
Selling, general and administrative

79,831

96,472

29,525

16,222

17,682

6,986

15,082

17,059

13,881

18,337

Research and development

38,820

49,008

14,784

9,790

13,803

18,509

24,578

23,043

11,456

28,590

Depreciation

-

-

-

-

-

-

1,165

1,292

1,075

1,403

Litigation (Note 19)

-

-

-

-

-

-

-

-

-

20,662

Purchase of in-process research and development (Note 8)

-

-

-

-

-

-

-

-

-

7,517

Restructuring charges

2,151

2,536

0

0

744

2,031

13,850

0

-

-263

Termination fee

-

-

0

-2,667

-28,400

-

-

-

-

-

Total operating expenses

120,802

148,016

44,309

23,345

3,829

-

-

-

-

-

Depreciation

-

-

-

-

-

964

-

-

-

-

Termination fee (Note 3)

-

-

-

-

-

0

0

-

-

-

Total expenses

-

-

-

-

-

28,490

54,675

41,394

26,412

96,444

Loss from operations

-50,067

-86,798

-36,706

-23,345

-3,829

-28,490

-54,675

-41,394

-26,412

-54,338

Interest expense, net

-50,498

-39,037

-2,960

277

113

-

-

-

-

-

Interest expense, net

-4,300

0

-

-

-

-

-

-

-

-

Fair value loss on investment

-

-

-10,740

0

0

-

-

-

-

-

Net foreign exchange loss

-

-

-

-

-

-32

-8

-148

363

7,003

Interest income

-

-

-

-

-

211

244

673

-

-

Interest income

-

-

-

-

-

-

-

-

1,834

4,339

Fair value change in contingent consideration (Notes 7, 14)

-

-

-

-

-

2,865

8,215

10,078

16,493

-

Other expense, net

-1,830

-292

-1,999

81

-481

207

-

-

-

-

Loss from continuing operations before income taxes

-

-

-

-

-4,197

-25,239

-46,164

-30,178

-7,144

-41,537

Interest expense

-

-

-

-

-

-

-

-

-

1,848

Fair value change in contingent consideration (Notes 7 and 10)

-

-

-

-

-

-

-

-

-

3,279

Other gains

-

-

-

-

-

-

60

613

578

28

Total other (expense) income

-

-

-

-

-

3,251

8,511

11,216

19,268

12,801

Loss before provision for income taxes

-106,728

-126,127

-52,405

-22,987

-

-

-

-

-

-

Benefit from (Provision for) income taxes

1,599

583

465

22

-192

599

-3,900

1,201

2,126

-5,317

Loss from continuing operations

-

-

-

-

-4,005

-

-

-

-

-

Loss from discontinued operations, net of income taxes

-

-

-

-

-66

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-108,300

-126,710

-52,870

-23,009

-4,071

-

-

-

-17,539

99,434

Loss from continuing operations

-

-

-

-

-

-25,838

-42,264

-31,379

-9,270

-36,220

(Loss) income from discontinued operations, net of income taxes (Note 12)

-

-

-

-

-

967

87,962

963

-

135,654

Net loss and comprehensive loss

-

-

-

-

-

-24,871

-

-

-

-

(Loss) Income from discontinued operations, net of income taxes (Note 8)

-

-

-

-

-

-

-

-

8,269

-

Net loss and comprehensive loss

-

-

-

-

-

-

45,698

-30,416

-

-

Continuing operations (in dollars per share)

-

-

-

-

-0.40

-0.51

-0.84

-0.63

-0.18

-

Discontinued operation (in dollars per share)

-

-

-

-

0.00

-

-

-

-

-

Discontinued operations

-

-

-

-

-

0.02

1.75

0.02

-0.15

-

Continuing operations

-

-

-

-

-

-

-

-

-

-0.64

Discontinued operations

-

-

-

-

-

-

-

-

-

2.41

Net loss per common share—basic and diluted (in usd per share)

-5.76

-6.81

-4.69

-2.20

-0.40

-0.49

0.91

-0.61

-0.33

1.77

Weighted-average shares outstanding—basic and diluted (in shares)

18,812

18,616

11,284

10,434

10,225

50,909

50,112

50

-

-

Basic

-

-

-

-

-

-

-

-

52,382

56,194

Diluted

-

-

-

-

-

-

-

-

52,382

56,194